Antifungal PK/PD considerations in fungal pulmonary infections

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 6, 2011, Pages 783-794

  Lepak, Alexander J ^a   Andes, David R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

antifungal; Aspergillus; pharmacodynamics; Pharmacokinetics; pulmonary

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG USE; HUMAN; LUNG ASPERGILLOSIS; LUNG INFECTION; MYCOSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FUNGI; HUMANS; LUNG DISEASES, FUNGAL; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

EID: 83655192876     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1295726     Document Type: Article

References (115)

1. Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998 26 1 1-10, quiz 1112
2. Ambrose P G., Bhavnani S M., Rubino C M. et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: its not just for mice anymore. Clin Infect Dis 2007 44 1 79-86 (Pubitemid 44968990)
3. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004 17 6 533-540 (Pubitemid 39627514)
4. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006 20 3 679-697 (Pubitemid 44375115)
5. Groll A H., Lyman C A., Petraitis V et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006 50 10 3418-3423 (Pubitemid 44527518)
6. Lewis R E., Liao G, Hou J, Chamilos G, Prince R A., Kontoyiannis D P. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007 51 4 1253-1258 (Pubitemid 46586802)
7. Groll A H., Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000 182 1 274-282 (Pubitemid 30497814)
8. Drugs@FDA. Diflucan [package insert]. 2011. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/ Accessed June 29, 2011
9. Drugs@FDA. Vfend [package insert]. 2011. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/ Accessed June 29, 2011
10. Drugs@FDA. Sporanox [package insert]. 2011. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/ Accessed June 29, 2011
11. Drugs@FDA. Noxafil [package insert]. 2011. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/ Accessed June 29, 2011
12. ODay D M., Foulds G, Williams T E., Robinson R D., Allen R H., Head W S. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol 1990 108 7 1006-1008 (Pubitemid 20216024)
13. Savani D V., Perfect J R., Cobo L M., Durack D T. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987 31 1 6-10 (Pubitemid 17212647)
14. Mian U K., Mayers M, Garg Y et al. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J Ocul Pharmacol Ther 1998 14 5 459-471 (Pubitemid 28489688)
15. Arndt C A., Walsh T J., McCully C L., Balis F M., Pizzo P A., Poplack D G. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988 157 1 178-180 (Pubitemid 18037468)
16. Foulds G, Brennan D R., Wajszczuk C et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988 28 4 363-366 (Pubitemid 19013387)
17. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003 56 Suppl 1 17-23 (Pubitemid 37491729)
18. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 37 5 728-732 (Pubitemid 37100817)
19. Hariprasad S M., Mieler W F., Holz E R. et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004 122 1 42-47 (Pubitemid 38063603)
20. Hyland R, Jones B C., Smith D A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003 31 5 540-547 (Pubitemid 36444162)
21. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 4 1570-1572
22. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008 46 2 201-211 (Pubitemid 351269158)
23. Denning D W., Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 34 5 563-571 (Pubitemid 34165316)
24. Barone J A., Moskovitz B L., Guarnieri J et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998 42 7 1862-1865 (Pubitemid 28311595)
25. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989 36 4 423-426 (Pubitemid 19140050)
26. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998 54 2 159-161 (Pubitemid 28204270)
27. Lange D, Pavao J H., Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997 37 6 535-540 (Pubitemid 27265655)
28. Barone J A., Koh J G., Bierman R H. et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993 37 4 778-784 (Pubitemid 23096878)
29. Johnson M D., Hamilton C D., Drew R H., Sanders L L., Pennick G J., Perfect J R. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003 51 2 453-457 (Pubitemid 36231176)
30. Barone J A., Moskovitz B L., Guarnieri J et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998 18 2 295-301 (Pubitemid 28145146)
31. Van de Velde V J., Van Peer A P., Heykants J J. et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996 16 3 424-428
32. Tucker R M., Denning D W., Arathoon E G., Rinaldi M G., Stevens D A. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990 23 3 Pt 2 593-601 (Pubitemid 20263686)
33. Rex J H., Pfaller M A., Galgiani J N. et al, Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997 24 2 235-247 (Pubitemid 127774263)
34. Denning D W., Tucker R M., Hanson L H., Hamilton J R., Stevens D A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989 149 10 2301-2308 (Pubitemid 19258176)
35. Denning D W., Tucker R M., Hanson L H., Stevens D A. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989 86 6 Pt 2 791-800 (Pubitemid 19148096)
36. Gubbins P O., Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006 50 6 1993-1999 (Pubitemid 43807517)
37. Ullmann A J., Cornely O A., Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006 50 2 658-666 (Pubitemid 43190980)
38. Kosoglou T, Perentesis G P., Affrime M B. et al. The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304. J Clin Pharmacol 1990 30 7 638-642 (Pubitemid 20241471)
39. Krishna G, Moton A, Ma L, Medlock M M., McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009 53 3 958-966
40. Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis 2008 46 10 1627, author reply 1627-1628 (Pubitemid 351706748)
41. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 48 9 3543-3551 (Pubitemid 39129357)
42. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004 48 3 804-808 (Pubitemid 38280328)
43. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004 57 2 218-222 (Pubitemid 38223535)
44. Walsh T J., Raad I, Patterson T F. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 1 2-12 (Pubitemid 44968977)
45. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 21 5 645-653 (Pubitemid 38447146)
46. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005 28 9 1805-1808 (Pubitemid 41324160)
47. Nivoix Y, Levêque D, Herbrecht R, Koffel J C., Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008 47 12 779-792
48. Drugs@FDA. Cancidas [package insert]. 2011. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/ Accessed June 29, 2011
49. Drugs@FDA. Mycamine [package insert]. 2011. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/ Accessed June 29, 2011
50. Drugs@FDA. Eraxis [package insert]. 2011. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/ Accessed June 29, 2011
51. Turnidge J D., Gudmundsson S, Vogelman B, Craig W A. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994 34 1 83-92 (Pubitemid 24237596)
52. Drusano G L. Antimicrobial pharmacodynamics: critical interactions of bug and drug Nat Rev Microbiol 2004 2 4 289-300 (Pubitemid 39490099)
53. Warn P A., Morrissey J, Moore C B., Denning D W. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother 2000 44 10 2664-2671
54. Denning D W., Warn P. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother 1999 43 11 2592-2599 (Pubitemid 29519535)
55. Klepser M E., Wolfe E J., Jones R N., Nightingale C H., Pfaller M A. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997 41 6 1392-1395 (Pubitemid 27231450)
56. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001 45 3 922-926 (Pubitemid 32182046)
57. Andes D, Safdar N, Marchillo K, Conklin R. Pharmacokinetic- pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006 50 2 674-684 (Pubitemid 43190982)
58. Ernst E J., Klepser M E., Pfaller M A. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000 44 4 1108-1111 (Pubitemid 30165304)
59. Ernst E J., Yodoi K, Roling E E., Klepser M E. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 2002 46 2 578-581 (Pubitemid 34087221)
60. Lewis R E., Wiederhold N P., Klepser M E. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005 49 3 945-951 (Pubitemid 40327708)
61. Wiederhold N P., Tam V H., Chi J, Prince R A., Kontoyiannis D P., Lewis R E. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006 50 2 469-473 (Pubitemid 43190954)
62. Hong Y, Shaw P J., Nath C E. et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006 50 3 935-942 (Pubitemid 43327797)
63. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999 43 9 2116-2120 (Pubitemid 29421186)
64. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003 47 4 1193-1199 (Pubitemid 36368574)
65. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003 47 10 3165-3169 (Pubitemid 37229574)
66. Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004 48 1 137-142 (Pubitemid 38040189)
67. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 2006 50 7 2374-2383 (Pubitemid 43993175)
68. Ernst E J., Klepser M E., Pfaller M A. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. Diagn Microbiol Infect Dis 1998 32 3 205-210 (Pubitemid 29017740)
69. Warn P A., Sharp A, Parmar A, Majithiya J, Denning D W., Hope W W. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009 53 8 3453-3461
70. Louie A, Drusano G L., Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998 42 5 1105-1109 (Pubitemid 28227905)
71. Baddley J W., Patel M, Bhavnani S M., Moser S A., Andes D R. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008 52 9 3022-3028
72. Rodríguez-Tudela J L., Almirante B, Rodríguez-Pardo D et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007 51 10 3599-3604 (Pubitemid 47519349)
73. Pai M P., Turpin R S., Garey K W. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007 51 1 35-39 (Pubitemid 46047684)
74. Pfaller M A., Diekema D J., Rex J H. et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006 44 3 819-826
75. Mavridou E, Brüggemann R J., Melchers W J., Mouton J W., Verweij P E. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010 54 2 860-865
76. Howard S J., Lestner J M., Sharp A et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 2011 203 9 1324-1332
77. Mavridou E, Bruggemann R J., Melchers W J., Verweij P E., Mouton J W. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010 54 11 4758-4764
78. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009 53 1 24-34
79. Ernst E J., Klepser M E., Ernst M E., Messer S A., Pfaller M A. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999 33 2 75-80 (Pubitemid 29115034)
80. Ernst E J., Roling E E., Petzold C R., Keele D J., Klepser M E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002 46 12 3846-3853 (Pubitemid 35403260)
81. Andes D, Diekema D J., Pfaller M A. et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008 52 2 539-550 (Pubitemid 351170826)
82. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003 47 4 1187-1192 (Pubitemid 36368573)
83. Andes D, Safdar N. Efficacy of micafungin for the treatment of candidemia. Eur J Clin Microbiol Infect Dis 2005 24 10 662-664 (Pubitemid 41667053)
84. Andes D R., Diekema D J., Pfaller M A., Marchillo K, Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008 52 10 3497-3503
85. Gumbo T, Drusano G L., Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007 51 3 968-974 (Pubitemid 46355282)
86. Gumbo T, Drusano G L., Liu W et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006 50 11 3695-3700 (Pubitemid 44684883)
87. Groll A H., Mickiene D, Petraitis V et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001 45 12 3322-3327 (Pubitemid 33107841)
88. Hope W W., Mickiene D, Petraitis V et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008 197 1 163-171 (Pubitemid 351263481)
89. Clancy C J., Huang H, Cheng S, Derendorf H, Nguyen M H. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother 2006 50 7 2569-2572 (Pubitemid 43993208)
90. Walsh T J., Lee J W., Kelly P et al. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother 1991 35 7 1321-1328
91. Kurtz M B., Heath I B., Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994 38 7 1480-1489 (Pubitemid 24203556)
92. Wiederhold N P., Kontoyiannis D P., Chi J, Prince R A., Tam V H., Lewis R E. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004 190 8 1464-1471 (Pubitemid 39332186)
93. Lewis R E., Albert N D., Kontoyiannis D P. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 2008 61 5 1140-1144 (Pubitemid 351524462)
94. Lewis R E., Leventakos K, Liao G, Kontoyiannis D P. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother 2011 55 7 3584-3587
95. Lewis R E., Liao G, Hou J, Prince R A., Kontoyiannis D P. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. J Antimicrob Chemother 2011 66 6 1324-1331
96. Perfect J R., Dismukes W E., Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010 50 3 291-322
97. Lewis R E., Prince R A., Chi J, Kontoyiannis D P. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002 46 10 3208-3214
98. Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006 194 7 1008-1018 (Pubitemid 44454087)
99. Clemons K V., Espiritu M, Parmar R, Stevens D A. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005 49 12 4867-4875 (Pubitemid 41778896)
100. Petraitis V, Petraitiene R, Hope W W. et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009 53 6 2382-2391
101. Petraitis V, Petraitiene R, Sarafandi A A. et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003 187 12 1834-1843 (Pubitemid 36724481)
102. Meletiadis J, Stergiopoulou T, OShaughnessy E M., Peter J, Walsh T J. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother 2007 51 6 2053-2064 (Pubitemid 46903094)
103. Kirkpatrick W R., Perea S, Coco B J., Patterson T F. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002 46 8 2564-2568 (Pubitemid 34793464)
104. Luque J C., Clemons K V., Stevens D A. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003 47 4 1452-1455 (Pubitemid 36368619)
105. MacCallum D M., Whyte J A., Odds F C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005 49 9 3697-3701 (Pubitemid 41233020)
106. Demchok J P., Meletiadis J, Roilides E, Walsh T J. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses 2010 53 3 239-245
107. OShaughnessy E M., Meletiadis J, Stergiopoulou T, Demchok J P., Walsh T J. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 2006 58 6 1168-1176 (Pubitemid 44884135)
108. Nivoix Y, Zamfir A, Lutun P et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006 52 1 67-74 (Pubitemid 43115510)
109. Singh N, Limaye A P., Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006 81 3 320-326 (Pubitemid 43255714)
110. Marr K A., Boeckh M, Carter R A., Kim H W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 6 797-802 (Pubitemid 39244292)
111. Denning D W., Marr K A., Lau W M. et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 5 337-349 (Pubitemid 44524711)
112. Kontoyiannis D P., Ratanatharathorn V, Young J A. et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009 11 1 89-93
113. Thomas A, Korb V, Guillemain R et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Ther 2010 35 1 49-53
114. Maertens J, Glasmacher A, Herbrecht R et al, Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006 107 12 2888-2897 (Pubitemid 44937044)
115. ClinicalTrials.gov. A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis. 2010. Available at: http://clinicaltrials.gov/C+2/show/NCT0053147 Accessed December 22, 2010